American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their results for follicular lymphoma (FL).
The key abstracts have been summarized in the table below:
Drug regimen
Abstract Title
Trial ID
Company
Class
ORR
CR
Odronextamab
Odronextamab in Patients with Relapsed/Refractory (R/R) Fol...
